• Advancing new drug treatments for billion dollar global disease markets

​

• Repurposed drugs have a much lower risk of failing in human trials

 

• Novel formulation opportunities for existing drugs - targeting improved patient compliance and the generation of intellectual property (IP)

 

• Highly capital efficient business model

 

• Experienced management team complemented by a network of experts

​